





Financial Calendar

2011

17 August	Annual profit and final dividend announcement
19 September	Shares traded ex-dividend
23 September	Record date for final dividend
14 October	Final dividend paid
19 October	Annual General Meeting
31 December	Half year ends

2012

22 February	Half year profit and interim dividend announcement
14 March	Shares traded ex-dividend
20 March	Record date for interim dividend
13 April	Interim dividend paid
30 June	Year ends
22 August	Annual profit and final dividend announcement
17 September	Shares traded ex-dividend
21 September	Record date for final dividend
12 October	Final dividend paid
17 October	Annual General Meeting
31 December	Half year ends

Cover: *Scientist Andrew Stalder and accountant Anna Osypenko both work for CSL in Parkville, Australia.*

Annual General Meeting

Wednesday 19 October 2011 at 10:00am
Function Centre, National Tennis Centre,
Melbourne Park, Batman Avenue, Melbourne 3000

AGM Live Webcast

The CSL Limited Annual General Meeting will be webcast through CSL's website: www.csl.com.au

Log on to the Home Page of CSL's website and then click on the item called Annual General Meeting webcast.

Share Registry


Computershare Investor Services Pty Limited
Yarra Falls, 452 Johnston Street Abbotsford VIC 3067
Postal Address: GPO Box 2975 Melbourne VIC 3001
Enquiries within Australia: 1800 646 882
Enquiries outside Australia: +61 3 9415 4178
Investor enquiries facsimile: +61 3 9473 2500
Website: www.investorcentre.com
Email: web.queries@computershare.com.au

2010-2011 Highlights


Dear Shareholder,

CSL achieved international sales growth for our plasma products this year in both established and emerging markets and continues to build the capacity to develop and produce new and improved therapies.

CSL Group Sales by Region 2010-11



CSL Group Sales by Major Products 2010-11



- > Net profit after tax was \$941 million for the twelve months ended 30 June 2011. This result has been achieved despite an unfavourable foreign exchange impact of \$116 million. On a constant currency basis¹, operational net profit after tax was \$1,057 million. CSL's balance sheet remains very strong with \$479 million cash on hand against borrowings of \$416 million. Cash flow from operations was \$1,018 million.
- > Our immunoglobulin portfolio achieved an outstanding result as transitions continued to Hizentra[®] from Vivaglobin[®], and to Privigen[®] from Carimune[®] and Sandoglobulin[®]. Strong sales in our critical care portfolio came from fibrinogen products Haemocompletan[®] and RiaSTAP[™], and from Berinert[®] our C1 esterase inhibitor for hereditary angioedema.
- > We continue to invest in manufacturing capacity to meet future demand for our products. We have expanded facilities in Bern and received approval by the US FDA and European regulatory authorities for our 20% subcutaneous immunoglobulin Hizentra[®]. In addition, capacity expansion has been completed in Marburg for several critical care products and a capacity upgrade has been initiated in Kankakee (US) for albumin.
- > We are going to build a 15 million gram capacity Privigen[®] facility at our Broadmeadows site in Melbourne. Expected to be in place by 2016, the facility will enhance operational integration with CSL Behring to maximise single platform efficiencies and support global demand.
- > We further progressed development of a family of recombinant coagulation therapies to treat bleeding disorders, concluded Phase III clinical trials for Beriplex[®] to arrest bleeding caused by anti-coagulant therapy and completed a Phase I safety study supporting the possible use of reconstituted high density lipoprotein, a potential additional breakthrough product made from human plasma.
- > Supporting our research and development activities, new facilities have been completed in Marburg for the purification and formulation of recombinant products, and construction of a new biotechnology facility commenced in Melbourne for late stage development of new therapies for cancer, bleeding disorders and inflammation.

¹ Constant currency removes the impact of exchange rate movements to facilitate comparability between 2010-11 and the prior year. For further details see opposite.

Financial Results

Financial highlights for the year ended 30 June 2011


Dividends to Shareholders

On 8 April 2011, shareholders received an interim unfranked dividend of 35 cents per share. A final dividend of 45 cents per share, franked to 2 cents per share, will be paid on 14 October 2011. Total ordinary dividends for the year were 80 cents per share.


Five Year Summary All figures are in \$A million unless stated otherwise ^(1,2)

	2010-11 Constant Currency ⁽²⁾	2010-11 Reported ⁽¹⁾	2009-10 Reported ⁽¹⁾	2008-09 Reported ⁽¹⁾	2007-08 Reported ⁽¹⁾	2006-07 Reported ⁽¹⁾
Total revenue	4,729	4,322	4,627	5,039	3,803	3,313
Sales revenue	4,584	4,188	4,456	4,622	3,557	3,172
R&D investment	344	325	317	312	225	191
Profit before income tax expense	1,340	1,198	1,379	1,370	952	774
Net profit	1,057	941	1,053	1,146	702	539
Capital investment		212	265	286	218	205
Total assets at 30 June		5,068	5,711	7,367	4,695	4,200
Total equity at 30 June		3,644	4,215	5,463	2,806	2,269
Net tangible assets per share at 30 June (\$) ⁽³⁾		5.20	5.93	7.43	3.44	2.44
Weighted average number of shares (million) ⁽³⁾		541	567	595	550	548
Basic earnings per share (cents) ⁽³⁾		174.0	185.8	192.5	127.6	98.5
Dividend per share (cents) ⁽³⁾		80.0	80.0	70.0	46.0	34.7


CSL Total Revenue
(\$A millions)




CSL Profit Before
Interest and Tax
(\$A millions)



CSL Net Profit
(\$A millions)



CSL R&D Investment
(\$A millions)



(1) The Group's Reported results are reported in accordance with the Australian Equivalents to International Financial Reporting Standards (A-IFRS).

(2) Constant currency removes the impact of exchange rate movements to facilitate comparability by restating the current year's results at the prior year's rates. This is done in two parts: 1) by converting the current year net profit of entities in the group that have reporting currencies other than Australian Dollars at the rates that were applicable to the prior year ("translation currency effect") and comparing this with the actual profit of those entities for the current year; and 2) by restating material transactions booked by the group that are impacted by exchange rate movements at the rate that would have applied to the transaction if it had occurred in the prior year ("transaction currency effect") and comparing this with the actual transaction recorded in the current year. The sum of translation currency effect and transaction currency effect is the amount by which reported net profit is adjusted to calculate the result at constant currency.

(3) Restated for the year ended 30 June 2007 following the 3 for 1 share split undertaken on 24 October 2007.

Board of Directors



Elizabeth Alexander, AM
Chairman



Brian McNamee, AO
Chief Executive Officer
and Managing Director



Peter Turner
Executive Director



John Akehurst



David Anstice



Bruce Brook



Christine O'Reilly



Ian Renard



Maurice Renshaw



John Shine, AO



David Simpson

Executive Management



Brian McNamee, AO
Chief Executive Officer
and Managing Director



Peter Turner
Executive Director



Paul Perreault
President, CSL Behring



Gordon Naylor
Chief Financial Officer



Andrew Cuthbertson
R&D Director and
Chief Scientific Officer



Jeff Davies
Executive Vice President,
CSL Biotherapies



Mary Sontrop
Executive Vice President,
CSL Behring Operations



Karen Etchberger
Executive Vice President,
Plasma, Supply Chain
and Information
Technology, CSL Behring



Greg Boss
CSL Group General
Counsel and Executive
Vice President,
CSL Behring



Edward Bailey
Company Secretary
and Australian General
Counsel



Jill Lever
Senior Vice President,
Human Capital



Paul Walton
Senior Vice President,
Corporate Development

Our Businesses

CSL Behring

CSL Behring is a global leader in biotherapies with the broadest range of quality products in our industry and substantial markets in the US, Europe and Japan.

Our therapies are indicated for treatment of coagulation disorders including haemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease.

CSL Behring products are also used to prevent haemolytic disease in newborns, speed recovery from heart surgery, prevent infection in people undergoing solid organ transplants, and help victims of shock and burns to recover faster.

CSL Biotherapies

CSL Biotherapies provides plasma fractionation services in Melbourne under contracts with Australia, New Zealand, Hong Kong, Malaysia, Singapore and Taiwan. We market commercial plasma products in Asia (excluding Japan) and we develop, manufacture and market immunohaematology products (diagnostic reagents) for Australia and Asia Pacific.

CSL Biotherapies manufactures and markets vaccines and pharmaceutical products in Australia and New Zealand and is responsible for global sales of our influenza vaccines.

Research and Development

CSL continues to invest in the development of protein-based medicines to treat serious human illnesses. Today, most of our licensed medicines are purified from human plasma or made from traditional sources. In addition, CSL is building the capabilities required to develop future products using recombinant DNA technology.

Global research and development activities support CSL's licensed product businesses and the development of new therapies focusing on products that align with our technical and commercial capabilities in immunoglobulins, specialty products, haemophilia and coagulation, breakthrough therapies and licensing.

Corporate Directory

Registered Head Office

CSL Limited

45 Poplar Road
Parkville
Victoria 3052
Australia

Phone: +61 3 9389 1911
Fax: +61 3 9389 1434

www.csl.com.au

Further Information

For further information about CSL and its operations, refer to Company announcements to the Australian Securities Exchange and our website:

www.csl.com.au

Share Registry

Computershare Investor Services Pty Limited

Yarra Falls
452 Johnston Street
Abbotsford VIC 3067

GPO Box 2975
Melbourne
Victoria 3001

Enquiries within Australia: 1800 646 882
Enquiries outside Australia: +61 3 9415 4178
Investor enquiries facsimile: +61 3 9473 2500
Website: www.investorcentre.com
Email: web.queries@computershare.com.au

Auditors

Ernst & Young

Ernst & Young Building
8 Exhibition Street
Melbourne
Victoria 3000

GPO Box 67
Melbourne Victoria 3001

Phone: +61 3 9288 8000
Fax: +61 3 8650 7777